This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kozloff MF , Martin LP , Krzakowski M , Samuel TA , Rado TA , Arriola E , De Castro Carpeno J , Herbst RS , Tarazi J , Kim S , Rosbrook B , Tortorici M , Olszanski AJ , Cohen RB
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
Br J Cancer. 2012 Oct 9;107(8) :1277-85
PMID: 22990652 PMCID: PMC3494447 URL: https://www.ncbi.nlm.nih.gov/pubmed/22990652
AbstractBACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumours. METHODS: In all, 49 patients received axitinib 5 mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort was enroled and received axitinib 5 mg b.i.d. with paclitaxel/carboplatin. RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (n=1) in the paclitaxel/carboplatin cohort and fatigue (n=1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%), diarrhoea (34.7%) and fatigue (28.6%). No grade >/=3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n=27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n=21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered alone or in combination. CONCLUSION: Axitinib 5 mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without evidence of overt drug-drug interactions. Both combinations demonstrated clinical efficacy and were well tolerated.
NotesKozloff, M F Martin, L P Krzakowski, M Samuel, T A Rado, T A Arriola, E De Castro Carpeno, J Herbst, R S Tarazi, J Kim, S Rosbrook, B Tortorici, M Olszanski, A J Cohen, R B eng P30 CA006927/CA/NCI NIH HHS/ Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't England Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18.